NU
Nassim Usman
President & Chief Executive Officer at Totus Medicines
South San Francisco, California
Overview
Nassim Usman is the President & CEO of Totus Medicines, where he oversees the company's strategic direction and executive leadership. With a background in cancer research and clinical trials, he has held significant roles in various biopharmaceutical companies, including serving as President & CEO of Catalyst Biosciences and holding positions on the boards of several biotech firms.
Usman has a strong track record in the pharmaceutical industry, having successfully led companies through various stages of growth, such as serving as CEO of Principia Biopharma and guiding Catalyst Biosciences through a successful IPO.
Work Experience
President & Chief Executive Officer
2023 - Current
Totus Medicines employs uses AI/ML and innovative DNA-encoded covalent library tech to discover small molecule medicines.
Raised $106,000,000.00 from Northpond Ventures, Regents of The University of Minnesota, Camford Capital and DCVC Bio.
Entrepreneur in Residence & Venture Partner
2005
Member Board of Directors
2023 - 2024
President & CEO, Member Board of Directors
2006 - 2023
Gyre Therapeutics is a biopharmaceutical company that focuses on developing and commercializing Hydronidone.
Member Board Of Directors
2011 - 2020
Mosaic Biosciences is your Discovery Partner in Protein and Antibody Therapeutics
Raised $14,674,000.00 from Telegraph Hill Partners and Dan Mitchell.
Member Board Of Directors
2011 - 2018
Principia Biopharma is dedicated to bringing oral therapies to patients with significant unmet medical needs in immunology & oncology.
Raised $337,799,978.00 from Mission BioCapital.
COO & CSO
2003 - 2005
Member Of The Supervisory Board
1999 - 2003
VP R&D & CSO
1992 - 2003
Postdoctoral Fellow, Staff Scientist
1987 - 1992